HemaSphere (Jun 2022)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA

  • Z. Zhuang,
  • Y. Tian,
  • L. Shi,
  • D. Zou,
  • R. Feng,
  • W.-W. Tian,
  • H. Yu,
  • F. Dong,
  • A. Liao,
  • Y. Ma,
  • Q. Liu,
  • S. Liu,
  • H. Jing,
  • R. Fu,
  • L.-M. Ma,
  • H. Liu,
  • W. Sun,
  • L. Bao,
  • Y. Wu,
  • W. Chen,
  • J. Zhuang

DOI
https://doi.org/10.1097/01.HS9.0000850984.40192.e8
Journal volume & issue
Vol. 6
pp. 1909 – 1910

Abstract

Read online

No abstracts available.